The results clearly demonstrate that not only is a combination of ERK1 and ERK2 superior in triggering a caspase-dependent mode of killing A375 melanoma cells compared to PLX4032 or PD0325901, but drug resistant clones infrequently appear by directly targeting ERK. The gene discussed is MAPK3; the disease is melanoma.